Insys Therapeutics Company Profile (NASDAQ:INSY)

About Insys Therapeutics

Insys Therapeutics logoInsys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: INSY
  • CUSIP:
Key Metrics:
  • Previous Close: $12.80
  • 50 Day Moving Average: $10.39
  • 200 Day Moving Average: $12.11
  • 52-Week Range: $8.70 - $21.22
  • Trailing P/E Ratio: 40.89
  • Foreward P/E Ratio: 40.00
  • P/E Growth: 0.55
  • Market Cap: $918.66M
  • Outstanding Shares: 71,770,000
  • Beta: 0.26
  • Net Margins: 8.71%
  • Return on Equity: 9.39%
  • Return on Assets: 7.09%
  • Current Ratio: 3.07%
  • Quick Ratio: 2.70%
Additional Links:
Companies Related to Insys Therapeutics:

Analyst Ratings

Consensus Ratings for Insys Therapeutics (NASDAQ:INSY) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $21.67 (69.27% upside)

Analysts' Ratings History for Insys Therapeutics (NASDAQ:INSY)
DateFirmActionRatingPrice TargetDetails
1/19/2017Oppenheimer Holdings, Inc.Reiterated RatingView Rating Details
1/8/2017RBC Capital MarketsSet Price TargetBuy$16.00View Rating Details
12/21/2016Royal Bank Of CanadaLower Price TargetOutperform$23.00 -> $16.00View Rating Details
10/10/2016Jefferies Group LLCReiterated RatingBuy$22.00 -> $18.00View Rating Details
8/25/2016Piper Jaffray CompaniesReiterated RatingOverweight$28.00View Rating Details
4/14/2016Janney Montgomery ScottInitiated CoverageBuy$22.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$38.00 -> $30.00View Rating Details
(Data available from 2/24/2015 forward)


Earnings History for Insys Therapeutics (NASDAQ:INSY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016Q316$0.02$0.07$55.97 million$55.20 millionViewN/AView Earnings Details
8/3/2016Q216$0.07$0.06$66.90 million$67.10 millionViewListenView Earnings Details
4/28/2016Q116$0.07$0.11$61.31 million$62.00 millionViewListenView Earnings Details
2/23/2016Q415$0.29$0.36$91.04 million$91.10 millionViewListenView Earnings Details
11/5/2015Q315$0.23$0.50$82.98 million$91.30 millionViewN/AView Earnings Details
8/6/2015Q215$0.21$0.21$74.06 million$77.60 millionViewN/AView Earnings Details
5/7/2015Q115$0.35$0.63$70.90 million$70.80 millionViewN/AView Earnings Details
3/3/2015Q414$0.44$0.53$63.50 million$66.50 millionViewN/AView Earnings Details
11/11/2014Q314$0.29$0.63$57.10 million$58.30 millionViewN/AView Earnings Details
8/12/2014Q214$0.30$0.58$52.77 million$55.70 millionViewN/AView Earnings Details
5/13/2014Q114$0.28$0.23$45.63 million$41.60 millionViewN/AView Earnings Details
3/4/2014Q413$0.55$0.71$34.73 million$40.20 millionViewN/AView Earnings Details
11/12/2013Q3$0.33$0.58$27.00 million$29.20 millionViewListenView Earnings Details
8/13/2013Q213$0.12$0.35$15.07 million$18.80 millionViewN/AView Earnings Details
6/3/2013Q113$0.01$2.00 million$11.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Insys Therapeutics (NASDAQ:INSY)
Current Year EPS Consensus Estimate: $0.31 EPS
Next Year EPS Consensus Estimate: $0.32 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.05$0.05$0.05
Q2 20161$0.04$0.04$0.04
Q3 20161$0.07$0.07$0.07
Q4 20161$0.11$0.11$0.11
(Data provided by Zacks Investment Research)


Dividend History for Insys Therapeutics (NASDAQ:INSY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Insys Therapeutics (NASDAQ:INSY)
Insider Ownership Percentage: 69.20%
Institutional Ownership Percentage: 45.21%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/4/2016Steven J MeyerDirectorBuy10,000$10.75$107,500.00View SEC Filing  
8/16/2016Theodore H StanleyDirectorSell15,000$18.02$270,300.00View SEC Filing  
8/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy5,700$18.57$105,849.00View SEC Filing  
8/11/2016Patrick FourteauDirectorSell15,000$18.46$276,900.00View SEC Filing  
8/9/2016Daniel BrennanVPSell5,781$19.16$110,763.96View SEC Filing  
6/6/2016Theodore H StanleyDirectorSell16,000$16.27$260,320.00View SEC Filing  
5/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy50,000$12.84$642,000.00View SEC Filing  
3/4/2016Patrick FourteauDirectorSell15,000$18.22$273,300.00View SEC Filing  
11/17/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy5,000$29.50$147,500.00View SEC Filing  
11/12/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy10,000$26.58$265,800.00View SEC Filing  
11/12/2015Patrick FourteauDirectorSell30,000$26.48$794,400.00View SEC Filing  
9/14/2015Theodore H. StanleyDirectorSell4,000$37.04$148,160.00View SEC Filing  
6/10/2015Fosse Franc DelGeneral CounselSell10,000$34.48$344,800.00View SEC Filing  
6/5/2015Steven J MeyerDirectorSell5,000$63.00$315,000.00View SEC Filing  
5/27/2015Brian TambiDirectorSell3,100$60.09$186,279.00View SEC Filing  
5/26/2015Brian TambiDirectorSell1,800$60.00$108,000.00View SEC Filing  
5/20/2015Patrick FourteauDirectorSell9,064$60.00$543,840.00View SEC Filing  
5/18/2015Darryl S BakerCFOSell10,000$59.17$591,700.00View SEC Filing  
5/11/2015Steven J MeyerDirectorSell18,000$57.06$1,027,080.00View SEC Filing  
3/17/2015Michael L BabichCEOSell75,000$58.63$4,397,250.00View SEC Filing  
3/11/2015Patrick FourteauDirectorSell10,000$59.94$599,400.00View SEC Filing  
3/10/2015Theodore H StanleyDirectorSell3,300$60.03$198,099.00View SEC Filing  
2/9/2015Darryl S BakerCFOSell30,000$52.23$1,566,900.00View SEC Filing  
11/19/2014Patrick FourteauDirectorSell25,000$39.11$977,750.00View SEC Filing  
11/4/2014Michael L BabichCEOSell80,000$38.66$3,092,800.00View SEC Filing  
8/13/2014Theodore H StanleyDirectorBuy3,000$33.93$101,790.00View SEC Filing  
6/16/2014John N KapoorDirectorBuy5,000$26.13$130,650.00View SEC Filing  
6/13/2014John N KapoorDirectorBuy5,000$25.44$127,200.00View SEC Filing  
6/12/2014John N KapoorDirectorBuy20,000$24.84$496,800.00View SEC Filing  
6/11/2014John N KapoorDirectorBuy20,000$24.54$490,800.00View SEC Filing  
5/19/2014Theodore StanleyDirectorBuy4,000$21.94$87,760.00View SEC Filing  
5/15/2014Patrick FourteauDirectorBuy7,500$22.77$170,775.00View SEC Filing  
3/5/2014Larry DillahaInsiderSell149,932$74.57$11,180,429.24View SEC Filing  
3/5/2014Michael BabichCEOSell288,432$74.58$21,511,258.56View SEC Filing  
1/16/2014Darryl BakerCFOSell10,000$49.61$496,100.00View SEC Filing  
1/15/2014Darryl BakerCFOSell10,000$47.54$475,400.00View SEC Filing  
1/14/2014Darryl BakerCFOSell10,000$45.64$456,400.00View SEC Filing  
12/9/2013John KapoorDirectorSell27,428$47.25$1,295,973.00View SEC Filing  
8/16/2013Michael BabichCEOBuy1,000$24.90$24,900.00View SEC Filing  
8/14/2013Patrick FourteauDirectorBuy5,000$23.77$118,850.00View SEC Filing  
6/4/2013Michael L BabichCEOBuy1,250$10.93$13,662.50View SEC Filing  
5/24/2013Pierre LapalmeDirectorBuy3,000$10.39$31,170.00View SEC Filing  
5/14/2013Patrick FourteauDirectorBuy5,000$10.90$54,500.00View SEC Filing  
5/13/2013Patrick FourteauDirectorBuy4,800$10.90$52,320.00View SEC Filing  
5/7/2013Patrick FourteauDirectorBuy50,000$8.36$418,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Insys Therapeutics (NASDAQ:INSY)
DateHeadline logoAlabama Doctors Convicted in Health-Care Fraud Case (NASDAQ:INSY) - February 23 at 10:59 PM logoForm 4 Insys Therapeutics, Inc. For: Feb 21 Filed by: KAPOOR JOHN N (NASDAQ:INSY) - February 23 at 10:59 PM logo[$$] Alabama Doctors Convicted in Health-Care Fraud Case (NASDAQ:INSY) - February 23 at 10:59 PM
News IconAmicus Therapeutics, Inc. (NASDAQ:FOLD) Insider Ownership stands at 1 (NASDAQ:INSY) - February 23 at 5:57 PM
News IconStock in Focus: INSYS Therapeutics, Inc. (NASDAQ:INSY) - Baldwin Journal (NASDAQ:INSY) - February 22 at 6:09 PM logoAre Options Traders Betting on a Big Move in Insys Therapeutics ... - Nasdaq (NASDAQ:INSY) - February 22 at 6:09 PM
News IconInsys Therapeutics Inc (NASDAQ:INSY) Might Be A Discount At Current Prices (NASDAQ:INSY) - February 22 at 12:37 PM
News IconSell-side Consensus on INSYS Therapeutics, Inc. (NASDAQ:INSY) Entercom Communications Corp. (NYSE:ETM) - Sherwood Daily (NASDAQ:INSY) - February 20 at 5:24 PM
News IconInsys Therapeutics, Inc. (NASDAQ:INSY) Price Target At $17.75 ... - Transcript Daily (NASDAQ:INSY) - February 20 at 5:24 PM
News IconHealthcare Shares Need To Consider: INSYS Therapeutics, Inc. (INSY), Edwards Lifesciences Corporation (NASDAQ:INSY) - February 18 at 5:20 PM
News IconBrokerage Firm Analyst Consensus on INSYS Therapeutics, Inc. (NASDAQ:INSY) Entercom Communications Corp ... - Sherwood Daily (NASDAQ:INSY) - February 18 at 12:12 PM
News IconNews Roundup: Sun Life Financial Inc. (NYSE:SLF), INSYS Therapeutics, Inc. (NASDAQ:INSY) - The Newburgh Press (NASDAQ:INSY) - February 18 at 12:12 PM logoHere's Why This Marijuana Stock Jumped 15% This Week (NASDAQ:INSY) - February 18 at 12:12 PM
News IconMSU Police submits request for arrest warrants in sexual assault investigation (NASDAQ:INSY) - February 17 at 4:16 PM
News IconTrading Update on Shares of Insys Therapeutics Inc. (INSY) - Baldwin Journal (NASDAQ:INSY) - February 17 at 12:01 PM logoINSYS Therapeutics, Inc.: Sudden move in price, will it continue? (NASDAQ:INSY) - February 17 at 12:01 PM logoBRIEF-Insys says Cannabidiol Oral Solution for compassionate use studies being provided at no cost (NASDAQ:INSY) - February 16 at 4:48 PM
News IconMedicinal Cannabis Industry Turns Toward Biopharma Influence for Competitive Advantages in Product Development (NASDAQ:INSY) - February 16 at 4:48 PM
News Icon$INSY Announces Use of Cannabidiol Oral Solution for Compassionate Use (NASDAQ:INSY) - February 16 at 4:48 PM
News IconImpact of Brokerage Rating on Insys Therapeutics, Inc.(INSY) (NASDAQ:INSY) - February 16 at 4:48 PM logoInsys Therapeutics Announces Use of Cannabidiol Oral Solution for Compassionate Use Studies in Patients Completing Long-Term Safety Study (NASDAQ:INSY) - February 16 at 4:48 PM logo7:04 am Insys Therapeutics is providing for the use of Cannabidiol Oral Solution at doses up to 40 mg/kg/day in compassionate use studies in subjects w/ epilepsyt in the ongoing long-term safety study (NASDAQ:INSY) - February 16 at 4:48 PM logoBiotech Industry Shaping up to Have a Breakout Year in 2017: Today's Reports on Insys Therapeutics and Zosano Pharma (NASDAQ:INSY) - February 16 at 4:48 PM logoInsys Therapeutics Announces Use of Cannabidiol Oral Solution for Compassionate Use Studies in Patients ... - Nasdaq (NASDAQ:INSY) - February 15 at 9:06 PM logoGurus' Worst Recent Investments (NASDAQ:INSY) - February 15 at 9:06 PM
News IconTechnical Review on Shares of INSYS Therapeutics, Inc. (NASDAQ:INSY) - Rives Journal (NASDAQ:INSY) - February 14 at 7:19 PM
News IconMarket Update: Watching Shares of Insys Therapeutics Inc. (INSY) - BVN (NASDAQ:INSY) - February 14 at 7:19 PM logoYet Another Indictment For An Insys Salesperson - Seeking Alpha (NASDAQ:INSY) - February 14 at 7:19 PM
News IconInsys Therapeutics, Inc. to Present at 2017 RBC Capital Markets Global Healthcare Conference - EconoTimes (NASDAQ:INSY) - February 14 at 7:19 PM logoInsys Therapeutics, Inc. to Present at 2017 RBC Capital Markets Global Healthcare Conference (NASDAQ:INSY) - February 14 at 5:24 PM
News IconConspiracy to Over Prescribe Opioids for Profit – Pharma Executives Arrested (NASDAQ:INSY) - February 14 at 12:02 AM
News IconPharma Executives Arrested In Conspiracy To Create Opioid Addicts For Profit (NASDAQ:INSY) - February 10 at 6:43 PM logoEx-Insys Sales Boss Indicted In Fentanyl Kickback Scheme (NASDAQ:INSY) - February 10 at 6:43 PM
News IconEquity in Review: Insys Therapeutics Inc. (INSY) - Providence Standard (NASDAQ:INSY) - February 8 at 11:43 PM logoShould You Buy Insys Therapeutics Inc (NASDAQ:INSY)? - Library For Smart Investors (NASDAQ:INSY) - February 8 at 11:43 PM logoINSYS Therapeutics, Inc. – Value Analysis (NASDAQ:INSY) : February 8, 2017 (NASDAQ:INSY) - February 8 at 6:42 PM logoINSYS Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : INSY-US : February 7, 2017 (NASDAQ:INSY) - February 7 at 7:15 PM logoBetter Marijuana Stock to Buy: GW Pharmaceuticals or Insys ... - Nasdaq (NASDAQ:INSY) - February 4 at 11:00 PM logoTrial Reveals Deep Ties Between Pair of Doctors and Fentanyl Maker (NASDAQ:INSY) - February 3 at 11:34 PM logoWhy This Marijuana Stock Surged 11.3% Higher in January (NASDAQ:INSY) - February 2 at 6:39 PM logoTrial Focuses on Ties Between Pain Doctors and Fentanyl Maker (NASDAQ:INSY) - February 1 at 6:42 PM logoGalena Sacks CEO Amid Escalating Criminal Probe Into Fentanyl Drug Marketing (NASDAQ:INSY) - January 31 at 6:42 PM logoInsys Therapeutics : Rochester mom suing drug maker recounts agony of withdrawal (NASDAQ:INSY) - January 30 at 10:45 AM
News IconStock Checkup: Technical Watch on Insys Therapeutics Inc. (INSY) - Rives Journal (NASDAQ:INSY) - January 28 at 11:04 PM
News Icon3 Best Marijuana Stocks to Watch in 2017 (NASDAQ:INSY) - January 27 at 7:55 PM logoResearch Reports Coverage on Biotech Stocks -- OncoGenex ... - PR Newswire (press release) (NASDAQ:INSY) - January 26 at 7:36 PM
News IconAnalyst Research Report on Insys Therapeutics, Inc. (INSY) - Highland Mirror (NASDAQ:INSY) - January 26 at 7:36 PM logoInsys Therapeutics : NH woman suing drug maker, physician's assistant (NASDAQ:INSY) - January 26 at 5:27 AM
News IconLawsuit filed against opioid drug maker, prescriber (NASDAQ:INSY) - January 25 at 7:23 PM
News IconInsys Therapeutics, Inc. (NASDAQ:INSY) Stock ABR At 1.6 - Stock Observer (NASDAQ:INSY) - January 24 at 11:43 PM


What is Insys Therapeutics' stock symbol?

Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY."

When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work?

Insys Therapeutics's stock split before market open on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly issued shares were payable to shareholders after the closing bell on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split.

Where is Insys Therapeutics' stock going? Where will Insys Therapeutics' stock price be in 2017?

7 equities research analysts have issued 1 year price targets for Insys Therapeutics' shares. Their forecasts range from $16.00 to $30.00. On average, they expect Insys Therapeutics' stock price to reach $21.67 in the next twelve months.

When will Insys Therapeutics announce their earnings?

Insys Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

Who owns Insys Therapeutics stock?

Insys Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (8.46%), Folger Hill Asset Management LP (1.72%), Dimensional Fund Advisors LP (0.80%), State Street Corp (0.63%), Credit Agricole S A (0.43%) and FMR LLC (0.36%). Company insiders that own Insys Therapeutics stock include Brian Tambi, Daniel Brennan, Darryl S Baker, Fosse Franc Del, John N Kapoor Trust Dated Sept, Michael L Babich, Patrick Fourteau, Steven J Meyer and Theodore H Stanley.

Who sold Insys Therapeutics stock? Who is selling Insys Therapeutics stock?

Insys Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, FMR LLC, Folger Hill Asset Management LP, Two Sigma Investments LP, Federated Investors Inc. PA, GSA Capital Partners LLP, Renaissance Technologies LLC and Dimensional Fund Advisors LP. Company insiders that have sold Insys Therapeutics stock in the last year include Daniel Brennan, Patrick Fourteau and Theodore H Stanley.

Who bought Insys Therapeutics stock? Who is buying Insys Therapeutics stock?

Insys Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Credit Agricole S A, A.R.T. Advisors LLC, Tudor Investment Corp Et Al and Menora Mivtachim Holdings LTD.. Company insiders that have bought Insys Therapeutics stock in the last two years include John N Kapoor Trust Dated Sept and Steven J Meyer.

How do I buy Insys Therapeutics stock?

Shares of Insys Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Insys Therapeutics stock cost?

One share of Insys Therapeutics stock can currently be purchased for approximately $12.80.

Insys Therapeutics (NASDAQ:INSY) Chart for Friday, February, 24, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Earnings History Chart

Earnings by Quarter for Insys Therapeutics (NASDAQ:INSY)

Dividend History Chart

Dividend Payments by Quarter for Insys Therapeutics (NASDAQ:INSY)

Last Updated on 2/24/2017 by Staff